Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TDS, OTC

Q Biomed Inc. to Present at Biotech Showcase(tm) 2018



NEW YORK, January 3, 2018 /PRNewswire/ --

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin, Chief Executive Officer, will present at the Biotech Showcase(tm) 2018 Conference to be held January 8 - 10, 2018 in San Francisco, California.

Details of QBioMed's' participation are as follows:


   
    Event:      Biotech Showcase(TM) 2018 Conference

    Date:       Tuesday, January 09, 2018
    Time:       4:00 p.m. Pacific Time
    Location:   Room: Franciscan - B (Ballroom Level)
                Hilton Hotel Union Square
                San Francisco


Biotech Showcasetm is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year.

Now in its tenth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.

In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals.

About Q BioMed Inc. 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact: 

Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

SOURCE Q BioMed Inc.


These press releases may also interest you

19 jan 2018
The food recall warning issued on January 12, 2018 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Imperial Caviar...

19 jan 2018
The National Safety Council extends its deepest sympathies to Tom Petty's family, friends, band members and millions of fans as they grapple not only with his loss, but also with the knowledge that the musical icon was taken far too soon because of a...

19 jan 2018
Exer More Than Urgent Care announced the healthcare company's inaugural community fundraising program, Exer Sports & Schools, raised over $51,000 for high school athletics across participating schools in 2017 and opened registration for the 2018...

19 jan 2018
Sanford Heisler Sharp, LLP today announced that San Diego's Scripps Health System has agreed to pay the United States Government more than $1.5 million to settle claims brought by a whistleblower under the False Claims Act. The suit was filed in...

19 jan 2018
Compassion & Choices today warned that the new "Conscience and Religious Freedom Division" in the U.S. Department of Health and Human Services (HHS) Office for Civil Rights threatens patients' legal rights to access all end-of life care options....

19 jan 2018
Hanger, Inc. , the  leading provider of orthotic and prosthetic patient care services and solutions, today announced the filing of its Annual Report on Form 10-K for the years ended December 31, 2016 and 2015 with the Securities and Exchange...




News published on 3 january 2018 at 10:49 and distributed by: